Key result
Prompt high-dose immunosuppression is critical for ICI myocarditis given its ~26% mortality.
Why the study?
Immune checkpoint inhibitor-associated myocarditis is a rare but life-threatening adverse event with limited evidence guiding diagnosis and immunosuppressive management.
This narrative review synthesizes current observational evidence and guidelines for the multidisciplinary diagnosis, risk stratification, and immunosuppressive management of immune checkpoint inhibitor-associated myocarditis.
Answers are grounded in this paper and cite their sources.
Supports prompt ICI-M recognition and corticosteroid use per IC-OS criteria; extends pathways but remains hypothesis-generating.
Immune checkpoint inhibitor-associated myocarditis (ICI-M) is a rare but life-threatening immune-related adverse event. Reported mortality ranges from 27 to 50% in earlier cohorts, with a more recent pooled estimate of approximately 26% in systematic reviews incorporating 2021 to 2022 data. Incidence is approximately 1%, rising to 2 to 4% with combination regimens. We performed a narrative review of the epidemiology, pathophysiology, overlap syndromes, risk stratification, diagnostic criteria, and immunosuppressive management of ICI-M. Diagnosis integrates an obligate rise in high-sensitivity troponin with multimodal imaging, framed by the International Cardio-Oncology Society (IC-OS) 2021 criteria and the 2024 American College of Cardiology (ACC) Consensus Pathway, after exclusion of acute coronary syndrome and infectious myocarditis. Risk stratification is discussed using a recently reported multivariable risk score. High-dose intravenous methylprednisolone is the accepted first-line therapy, with observational data associating higher initial dosing with more favourable biomarkers and survival trends. Up to half of severe cases fail first-line therapy and require escalation. Evidence for second-line agents, including mycophenolate mofetil, tacrolimus, abatacept, anti-thymocyte globulin, infliximab, tocilizumab, and ruxolitinib, derives from case series and small cohorts rather than randomised trials, and is presented with that limitation stated. ICI-M requires a structured, multidisciplinary approach integrating early recognition, systematic risk stratification, prompt high-dose immunosuppression, and a structured escalation approach for steroid-refractory disease, recognising that second-line evidence remains limited. This review synthesises the current, largely observational evidence to support individualised multidisciplinary management, and distinguishes guideline-endorsed recommendations from areas resting on limited or emerging data.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2026) conducted a review in Immune checkpoint inhibitor-associated myocarditis. Immunosuppressive therapy (corticosteroids and second-line agents) was evaluated. Immune checkpoint inhibitor-associated myocarditis is a life-threatening complication with approximately 26% mortality, requiring early recognition and prompt high-dose immunosuppression.
Synapse has enriched 10 related papers. Consider them for comparative context: